• Silatronix

  Participated · Equity · Jun 2016

  Silatronix develops patented organosilicon (OS) materials for use in lithium‑ion batteries, including electrolytes, binders, and coatings. Its first commercial product, OS3, is an advanced functional solvent that inhibits LiPF6 breakdown, is thermally and electrochemically stable, and has minimal side effects on battery performance. The company reports progress with multiple customers—many in Asia—across consumer electronics, industrial, automotive, and military battery applications. Silatronix raised US$8M in new equity capital to support commercialization and operational scale‑up. The firm is formalizing relationships with strategic suppliers, expanding its Madison, Wisconsin facilities, working with distribution partner Inabata to increase market presence, and hiring key operating personnel. Management says the funding and partnerships will allow Silatronix to capitalize on the commercial value of its OS materials in the high‑growth LiB market.

• Biocartis

  Participated · Equity · Sep 2014

  Biocartis develops Idylla, a miniaturized, fully automated molecular system that integrates all molecular diagnostics steps and delivers results in 35–120 minutes; the system and its first assay have CE‑IVD marking. The company plans to use the new capital to fund the commercial roll-out of Idylla in Europe later this year and to expand commercial reach beyond Europe next year. Proceeds will also support and accelerate development of a broad assay menu across oncology, infectious diseases and other applications. With the EUR 64.5 million equity round, total capital invested in Biocartis to date amounts to EUR 240 million (approx. USD 316 million). Biocartis has separated its Evalution business unit and combined it with Pronota to form MyCartis, which will continue biomarker panel development in Ghent and maintain activities in Switzerland. The Evalution platform (previously DMAT) is positioned as a molecular biomarker multiplexing technology for clinical and pharmaceutical applications. Biocartis is developing the Idylla molecular diagnostics platform and a range of assays with an initial focus on oncology. It completed a EUR 30 million Series E equity fundraising to validate Idylla and its first assay and to continue assay development. The round was entirely subscribed by existing shareholders such as RMM (Rudi Mariën), Debiopharm Diagnostics SA, PMV Tina Fund, Valiance, Johnson & Johnson Development Corporation, Philips, the Wellcome Trust, Petercam, the family offices of Dr. Paul Janssen, Luc Verelst, Rudi Pauwels, and some smaller shareholders including employees. Biocartis said the funding positions it to unroll an ambitious commercialization plan in 2014 and expects to launch the Idylla platform and a BRAF cancer assay in the second half of 2014. Idylla is described as a compact, scalable platform that allows assays to be performed anywhere without a specialist laboratory or trained technicians, rapidly detecting biomarkers with higher sensitivity than standard diagnostic assays and sequencing. Management signalled a goal of becoming a fully integrated global diagnostics company and will use the proceeds to advance validation, assay development, and commercial preparation. Biocartis develops clinically relevant molecular diagnostic tests and easy-to-use, fully automated platforms with a primary focus on oncology. The company will use a 1.9M subsidy from the Belgian Agency for Innovation by Science and Technology (IWT) to accelerate a two-year project to develop new cancer assays. The planned tests will detect known, validated oncogenes and focus on skin, colon and lung cancers to enable more targeted treatment. Biocartis will also create assays that permit simultaneous detection of dozens of parameters for its recently launched multiplex detection platform aimed at the research market. Founded in 2007 and based at EPFL’s Innovation Square in Lausanne, the company has fully owned subsidiaries in Mechelen (Belgium) and Eindhoven (Netherlands). Biocartis employs over 150 people and has raised close to EUR 150 million in equity to date. Biocartis is a Lausanne, Switzerland-based molecular diagnostics company that develops and commercializes diagnostic platforms and clinically relevant oncology assays. Its core product effort includes the Apollo platform, which the company intends to validate, register and launch. The company plans to continue developing its oncology tests and to grow its commercial presence. Biocartis completed a €34.5m (approximately $45m, CHF 42m) Series D equity funding to support those efforts. As part of the financing, Roald Borré, representing the lead investor PMV, will join Biocartis’ board. The company is led by CEO Greg Parekh and chairman and founder Rudi Pauwels. Biocartis develops and commercializes compact molecular diagnostic systems and completed a €71m (US$100m) Series C equity financing. The company intends to use the funds to commercialize its first product and other diagnostic applications. Biocartis will launch its first system, Apollo, in 2013; Apollo was developed in close collaboration with Philips Corporate Technologies to enable personalized medicine and individual diagnoses. Apollo is a compact system that allows multiple assays to be performed anywhere, rapidly and without the need for a specialist laboratory environment or trained technicians. Founded in 2007 and based in Lausanne, Switzerland, Biocartis also operates a fully owned Belgian subsidiary in Mechelen and a Dutch subsidiary at the High Tech Campus in Eindhoven. Following the fundraise, the company plans to enlarge its Board and adjust its membership.

No current team members are available.